References
- Dennehy PH. Rotavirus vaccines: an overview. Clin. Microbiol. Rev.21, 198–208 (2008).
- Parashar UD, Gibson CJ, Bresee JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg. Infect. Dis.12, 304–306 (2006).
- Fischer TK, Viboud C, Parashar U et al. Hospitalizations and deaths from diarrhea and rotavirus among children <5 years of age in the United States, 1993 – 2003. J. Infect. Dis.174, S47–S50 (2007).
- O’Ryan M. Rotarix™ (RIX 4414): an oral human rotavirus vaccine. Expert Rev. Vaccines6, 11–19 (2007).
- Soriano-Gabarro M, Mrukowicz J, Vesikari T, Verstraeten T. Burden of rotavirus disease in European Union countries. Pediatr. Infect. Dis. J.25(Suppl. 1), S7–S11 (2006)
- Clark HF, Offit PA, Ellis RW et al. The development of multivalent bovine rotavirus (strain wc3) reassortant vaccine for infants. J. Infect. Dis.174, S73–S80 (1996).
- Clark HF, Offit PA, Ellis RW et al. WC3 reassortant vaccines in children: brief review. Arch. Virol.12, 187–198 (1996).
- Clark HF, Borian FE, Modesto K, Plotkin SA. Serotype 1 reassortant of bovine rotavirus WC3, strain W179–9, induces a polytypic antibody response in infants. Vaccine8, 327–332 (1990).
- Clark HD, Borian FE, Plotkin SA. Immune protection of infants against rotavirus gastroenteritis by a serotype 1 reassortant of bovine rotavirus WC3. J. Infect. Dis.161, 1099–1104 (1990).
- Christy C, Offit P, Clark HF, Treanor J. Evaluation of a bovine-human rotavirus reassortant vaccine in infants. J. Infect. Dis.168, 1598–1599 (1993).
- Treanor JJ, Clark HF, Pichichero M et al. Evaluation of the protective efficacy of a serotype 1 bovine – human rotavirus reassortant vaccine in infants. Pediatr. Infect. Dis. J.14, 301–307 (1995).
- Clark HF, Bernstein DI, Dennehy PH et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human–bovine reassortant rotavirus vaccine in healthy infants. J. Pediatr.144, 184–190 (2004)
- Clark HF, Burke CJ, Volkin DB et al. Safety, immunogenicity, and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Pediatr. Infect. Dis. J.22, 914–920 (2003).
- Vesikari T, Clark HF, Offit PA et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety, and immunogenicity in infants. Vaccine24, 4821–4829 (2006).
- Vesikari T, Matson DO, Dennehy P et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N. Engl. J. Med.354, 23–33 (2006).
- Vesikari T, Itzler R, Matson DO et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated healthcare utilization across three regions (11 countries). Int. J. Infect. Dis.11(Suppl. 2), S29–S35 (2007).
- RotaTeq™, package insert. Merck, NJ, USA.
- Goveia MG, Rodriguez ZM, Dallas MJ et al. Safety and efficacy of the pentavalent human–bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatr. Infect. Dis. J.26, 1099–1104 (2007).
- Goveia MG, DiNubile MJ, Dallas MJ et al. Efficacy of pentavalent human–bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatr. Infect. Dis. J.27, 656–658 (2008).
- Dennehy PH, Goveia MG, Dallas MJ, Heaton PM. The integrated Phase III safety profile of the pentavalent human–bovine (WC3) reassortant rotavirus vaccine. Int. J. Infect. Dis.11(Suppl. 2), S36–S42 (2007).
- Ciarlet M, Sani-Grosso R, Yuan G et al. Safety and immunogenicity of concomitant use of the pentavalent rotavirus vaccine (RotaTeq) and oral poliovirus vaccine (OPV). Presented at: European Society for Pediatric Infectious Diseases (ESPID). Porto, Portugal, 2–4 May 2007.
- Committee on Infectious Diseases. Prevention of rotavirus disease: guidelines for use of rotavirus vaccine. Pediatrics119, 171–182 (2007).
- Velazquez FR, Matson DO, Calva JJ et al. Rotavirus infection in infants as protection against subsequent infections. N. Engl. J. Med.335, 1022–1028 (1996).
- Rodriguez ZM, Goveia MG, Stek JE et al. Concomitant use of an oral live pentavalent human–bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatr. Infect. Dis. J.26, 221–227 (2007).
- Haber P, Patel M, Izurieta HS et al. Postlicensure monitoring of intusussception after RotaTeq vaccination in the United States, February 1, 2006 – September 25, 2007. Pediatrics121, 1206–1212 (2008).
- Matson DO. The pentavalent rotavirus vaccine, RotaTeq™. Semin. Pediatr. Infect. Dis.17, 195–199 (2006).
- Glass RI, Bresee JS, Turcios R, Fischer TK, Parashar UD, Steele AD. Rotavirus vaccines: targeting the developing world. J. Infect. Dis.192, S160–S166 (2005).